S

Summit Therapeutics
D

SMMT

19.450
USD
-0.03
(-0.15%)
Market Closed
Volume
55,285
EPS
0
Div Yield
0
P/E
-177
Market Cap
14,293,613,787
OverviewSignalsIdeasNews
Related Instruments
    B
    BLCM
    -0.01620
    (-4.09%)
    0.36000 USD
    B
    BLUE
    -0.06000
    (-5.26%)
    1.08000 USD
    C
    CRSP
    -2.450
    (-4.28%)
    54.840 USD
    E
    EDIT
    -0.28500
    (-5.26%)
    5.13500 USD
    F
    FGEN
    -0.05200
    (-9.77%)
    0.48000 USD
    K
    KPTI
    -0.06290
    (-6.37%)
    0.92380 USD
    M
    MDGL
    -6.22
    (-2.18%)
    278.97 USD
    Q
    QURE
    -0.14500
    (-1.89%)
    7.51000 USD
    R
    RARE
    -0.870
    (-1.93%)
    44.140 USD
    S
    SRPT
    1.650
    (1.16%)
    144.000 USD
    More
News

Title: Summit Therapeutics

Sector: Healthcare
Industry: Biotechnology
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate isridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.